Trial Profile
Phase I/prospective randomized phase II trial Of the Safety and Efficacy of tamoxifen in combination with the Isoform selective Pi3K inhibitor GDC-0032 compared with tamoxifen alONe in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment (POSEIDON trial)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 20 Dec 2022
Price :
$35
*
At a glance
- Drugs Taselisib (Primary) ; Tamoxifen
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms POSEIDON
- 11 Oct 2022 Status changed from suspended to completed.
- 21 Mar 2022 Planned End Date changed from 1 Jul 2022 to 1 Dec 2022.
- 21 Mar 2022 Planned primary completion date changed from 1 Jan 2022 to 1 Jul 2022.